OncoMatch/Clinical Trials/NCT06670196
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Is NCT06670196 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SKB264 and Osimertinib for non-small cell lung cancer.
Treatment: SKB264 · Osimertinib — The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with osimertinib as first-Line treatment for patients with epidermal growth factor receptor (EGFR) mutations, locally advanced or metastatic non-squamous non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
No prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC
Cannot have received: targeted TROP2 therapy
Targeted TROP2 therapy
Cannot have received: topoisomerase I inhibitor
Any drug therapy that targets topoisomerase I, including antibody-drug conjugates (ADCs)
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify